Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Invitae gets court approval for five-month bankruptcy sale

Published 02/15/2024, 02:09 PM
Updated 02/15/2024, 02:11 PM
© Reuters. FILE PHOTO: Invitae Corporation CEO Randy Scott (R ) looks up at the price for his genetic company during the IPO on the floor of the New York Stock Exchange February 12, 2015. REUTERS/Brendan McDermid/File Photo

By Dietrich Knauth

NEW YORK (Reuters) - Invitae (OTC:NVTA) Corp received court approval on Thursday to run a five-month bankruptcy sale process, allowing the genetic testing company to find a buyer and exit from Chapter 11 by late July.

U.S. Bankruptcy Judge Michael Kaplan approved the Softbank-backed company's proposed bid procedures at a court hearing in Trenton, New Jersey, setting an April 10 deadline for initial bids and scheduling an auction for April 17.

Invitae, which filed for bankruptcy protection on Tuesday, intends to seek court approval of the sale on May 6 and expects to close the transaction by July 21.

Invitae does not expect equity shareholders to receive any recovery in its bankruptcy, according to court documents. It has about $1.5 billion in debt. Its bankruptcy petition estimated that its total assets are worth between $500 million and $1 billion.

Invitae began reaching out to potential buyers in December, and it has already received some initial bids, Invitae attorney Nicole Greenblatt told Kaplan.

Greenblatt said Invitae went bankrupt because it took on too much debt to fund its expansion from 2019 to 2021. Invitae made 13 acquisitions during that period, increasing its debt by $1.5 billion and leaving the company ill-prepared for a recent rise in interest rates, increased competition, and declining demand for elective genetic tests.

"While these acquisitions helped Invitae expand into new markets and round out its product portfolio and improve customer experience, they also required large sums of capital for investment and significant operating expenses," Greenblatt said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Invitae began taking steps to reduce its debt in 2022, terminating 1,200 employees, downsizing office space and testing labs, and selling off unprofitable, non-core businesses, the company said in court filings.

Invitae's divestitures included companies that it acquired during its $1.5 billion acquisition spree, such as Ciitizen, an AI-focused patient network business that Invitae acquired in 2021 for $325 million.

Those moves saved Invitae approximately $326 million in annual costs, but were not enough to turn a profit, according to court filings. Invitae reported a $1.3 billion net loss for the first nine months of 2023.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.